![]() | |
Clinical data | |
---|---|
Other names | HM95573
GDC5573 RG6185 |
Routes of administration | By mouth |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C23H16ClFN6OS |
Molar mass | 478.93 g·mol−1 |
3D model (JSmol) | |
| |
|
Belvarafenib (developed by Hanmi Pharmaceuticals and Genentech) is a small molecule RAF dimer (type II) inhibitor[1] which shows anti-tumor clinical activity in cancer patients with BRAFV600E- and NRAS- mutations.[2]
![]() | This antineoplasticorimmunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |